^
Association details:
| Biomarker: | POMK-NRG1 fusion + KRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series
Published date:
08/27/2020
Excerpt:
The patient with colorectal cancer harbored a novel POMK-NRG1 fusion and a KRAS mutation…patient received afatinib as fifteenth-line therapy....The latter include several with a prolonged response to treatment (>18 months), as well as the first report of efficacy in NRG1 fusion-positive colorectal cancer.
DOI:
10.1634/theoncologist.2020-0379
